Kingswood Wealth Advisors LLC Increases Stake in AbbVie Inc. $ABBV

Kingswood Wealth Advisors LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 125.7% during the third quarter, Holdings Channel.com reports. The firm owned 25,172 shares of the company’s stock after acquiring an additional 14,017 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in AbbVie were worth $5,828,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie in the second quarter worth about $25,000. Evolution Wealth Management Inc. bought a new position in AbbVie during the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC purchased a new position in AbbVie in the 2nd quarter worth approximately $28,000. Financial Gravity Companies Inc. purchased a new position in AbbVie in the 2nd quarter worth approximately $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in AbbVie in the second quarter valued at approximately $39,000. 70.23% of the stock is owned by institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline/clinical progress — AbbVie advanced its icalcaprant (depression) Phase 2 program, which supports medium‑term pipeline optionality beyond its core immunology/oncology franchises. AbbVie Advances Icalcaprant Trial in Depression: What Investors Should Watch
• Positive Sentiment: Early‑stage oncology expansion — AbbVie launched a first‑in‑human trial for ABBV‑901 in ovarian cancer, increasing optional upside if the program shows early signal. AbbVie Expands Ovarian Cancer Pipeline With New First‑in‑Human ABBV‑901 Trial
• Positive Sentiment: Analyst support — Berenberg issued a buy on ABBV, giving some near‑term credibility to upside narratives and providing a buy signal for income/value investors. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Dividend/income appeal — commentary highlighting AbbVie’s yield and steady dividend profile is keeping income‑focused investors engaged despite valuation premium. AbbVie: The Dividend Does Not Lie
• Neutral Sentiment: Real‑world study readouts — post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped, which may gradually support label expansion and payer confidence but are not immediate revenue catalysts. AbbVie’s Korean Rinvoq Study in IBD Wraps Up, Setting the Stage for New Real‑World Data
• Neutral Sentiment: Upcoming results call — AbbVie set its full‑year and Q4 earnings release and Feb. 4 conference call; investors will watch guidance reconciliation and quarterly details for clarity. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Negative Sentiment: Guidance slightly below consensus — AbbVie trimmed/updated Q4 and FY‑2025 EPS ranges that sit at or just below street consensus, which likely pressured the stock as investors reprice near‑term growth expectations.
• Negative Sentiment: One‑time IPR&D/R&D charges — management flagged IPR&D and related expenses that will negatively impact Q4 EPS, creating near‑term earnings noise ahead of the February print. AbbVie sees negative Q4 EPS impact from IPR&D expenses
• Negative Sentiment: Failed takeover optimism — earlier media reports that AbbVie was in talks to buy Revolution Medicines briefly lifted sentiment; AbbVie subsequently denied talks, prompting disappointment and a reversal in momentum. AbbVie Denies It’s in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

AbbVie Trading Down 3.9%

NYSE:ABBV opened at $224.22 on Friday. The company has a 50-day moving average price of $226.55 and a 200-day moving average price of $214.86. The stock has a market cap of $396.28 billion, a price-to-earnings ratio of 169.86, a P/E/G ratio of 0.98 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the company earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 496.97%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ABBV shares. Raymond James Financial set a $256.00 target price on shares of AbbVie in a report on Monday, November 3rd. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. UBS Group began coverage on shares of AbbVie in a report on Wednesday. They issued a “neutral” rating and a $240.00 price target on the stock. Citigroup lowered their price objective on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Finally, Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $246.89.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.